Literature DB >> 28877311

Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

Dae Hyun Kim1,2, Hajime Uno3, Lee-Jen Wei4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28877311      PMCID： PMC6359932          DOI： 10.1001/jamacardio.2017.2922

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  7 in total

Review 1.  Evidence-based risk communication: a systematic review.

Authors:  Daniella A Zipkin; Craig A Umscheid; Nancy L Keating; Elizabeth Allen; KoKo Aung; Rebecca Beyth; Scott Kaatz; Devin M Mann; Jeremy B Sussman; Deborah Korenstein; Connie Schardt; Avishek Nagi; Richard Sloane; David A Feldstein
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

2.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Samir R Kapadia; Martin B Leon; Raj R Makkar; E Murat Tuzcu; Lars G Svensson; Susheel Kodali; John G Webb; Michael J Mack; Pamela S Douglas; Vinod H Thourani; Vasilis C Babaliaros; Howard C Herrmann; Wilson Y Szeto; Augusto D Pichard; Mathew R Williams; Gregory P Fontana; D Craig Miller; William N Anderson; Jodi J Akin; Michael J Davidson; Craig R Smith
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

4.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.

Authors:  Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson
Journal:  Lancet       Date:  2015-03-15       Impact factor: 79.321

5.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

6.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

7.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2013-12-07       Impact factor: 4.615
  7 in total
  47 in total

1.  Predicting Mortality and Adverse Outcomes: Comparing the Frailty Index to General Prognostic Indices.

Authors:  Sandra M Shi; Ellen P McCarthy; Susan L Mitchell; Dae Hyun Kim
Journal:  J Gen Intern Med       Date:  2020-02-18       Impact factor: 5.128

2.  Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks.

Authors:  Lihui Zhao; Lu Tian; Brian Claggett; Marc Pfeffer; Dae Hyun Kim; Scott Solomon; Lee-Jen Wei
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

3.  An Alternative Approach for the Analysis of Time-to-Event and Survival Outcomes in Pulmonary Medicine.

Authors:  Michael O Harhay; Raphaël Porcher; Edward Cantu; Michael J Crowther; Jason D Christie; Gabriel Thabut; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

4.  Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome: A Decision Analysis.

Authors:  Sarah S Pickard; John B Wong; Emily M Bucholz; Jane W Newburger; Wayne Tworetzky; Terra Lafranchi; Carol B Benson; Louise E Wilkins-Haug; Diego Porras; Ryan Callahan; Kevin G Friedman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-04-07

5.  The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.

Authors:  Xianmixikemaier Abulizi; Heather J Ribaudo; Philippe Flandre
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

6.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

7.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

8.  Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-03-31

9.  Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.

Authors:  Catherine Lee; Devon K Check; Leslie Manace Brenman; Lawrence H Kushi; Mara M Epstein; Christine Neslund-Dudas; Pamala A Pawloski; Ninah Achacoso; Cecile Laurent; Louis Fehrenbacher; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2020-01-23       Impact factor: 4.872

10.  Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.

Authors:  Ariela R Orkaby; Michael W Rich; Ryan Sun; Eliah Lux; Lee-Jen Wei; Dae Hyun Kim
Journal:  J Am Geriatr Soc       Date:  2018-09-25       Impact factor: 5.562
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.